{"filing":{"accession_number":"0001193125-26-384355","cik":"0001778016","ticker":"NBP","company_name":"NovaBridge Biosciences","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"6-k_new_director_martin.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1778016/000119312526384355/6-k_new_director_martin.htm"},"events":[{"id":31754,"run_id":29156,"accession_number":"0001193125-26-384355","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The exhibit announces the appointment of Martin Dewhurst to NovaBridge's Board of Directors as an independent director and member of the Audit and Compensation Committees, effective immediately. This is a clear governance event involving the appointment of a named executive/director with substantial healthcare and board experience. The disclosure also notes the concurrent departure of independent director Liu Xin, but the principal action disclosed is Dewhurst's appointment to the board and committees.","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":34731,"accession_number":"0001193125-26-384355","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the appointment of Martin Dewhurst to NovaBridge's Board of Directors as an independent director and member of the Audit and Compensation Committees, effective immediately. This is a clear governance event involving the appointment of a named executive/director with substantial healthcare and board experience. The disclosure also notes the concurrent departure of independent director Liu Xin, but the principal action disclosed is Dewhurst's appointment to the board and committees.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:01:41.552014+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34731,"accession_number":"0001193125-26-384355","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the appointment of Martin Dewhurst to NovaBridge's Board of Directors as an independent director and member of the Audit and Compensation Committees, effective immediately. This is a clear governance event involving the appointment of a named executive/director with substantial healthcare and board experience. The disclosure also notes the concurrent departure of independent director Liu Xin, but the principal action disclosed is Dewhurst's appointment to the board and committees.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:01:41.552014+00:00","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-09-08"}]}